Seattle, United States
Outpace Bio, founded in 2020, is at the forefront of cell therapy innovation, leveraging advanced protein design to revolutionize treatment options, particularly targeting solid tumors. With their slogan, "Revolutionizing Cell Therapy with Protein Design", the company promises transformative advancements in the Biotechnology, Health Care, Life Sciences, and Pharmaceutical industries.
Headquartered in the United States, Outpace Bio is developing a comprehensive suite of technologies, such as OutLast™, OutSmart™, OutSpacers™, Co-LOCKR™, and EGFRopt™, each designed to enhance the efficacy, specificity, and safety of cell therapies. Their internal and collaborated pipeline ensures rapid technological validation across varied cell types and manufacturing methods.
The company recently secured a $144.00M Series B investment on 01 August 2024 with participation from notable investors including ARTIS Ventures, Abstract Ventures, Civilization Ventures, RA Capital Management, and Bristol-Meyers Squibb, among others. This influx of capital signals investor confidence in their vision to deliver curative therapies.
